arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

EXELIXIS, INC.

EXEL
$54.08 ▲ +1.85 (+3.54%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
67 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
90
Health
Excellent
Bullish
auto_awesome

Analytical Summary

EXELIXIS, INC. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $14.0B
Dividend Yield
Revenue Growth 10.0%
Op. Margin 41.1%
ROIC 10.3%
FCF / Share $0.97
Trailing P/E 66.8x
Price / Book 7.1x
FCF Yield 1.8%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

67-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$610.81M
↑ +10.0%
Net Income Profit after all expenses
$210.47M
↑ +31.9%
Operating Margin Operating profit as % of sales
41.1%
↑ +4.7% 92th
FCF / Share Free cash flow per share
$0.97
↑ +29.6%
Long-Term Debt Long-term obligations
$0.00
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
94
Returns
95
Cash Quality
70

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters